Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897): An intensive and effective regimen for patients with aggressive, refractory or recurrent non-Hodgkin lymphomas after anthracycline-containing regimens

Cancer

Volumn 104, Issue 3, 2005, Pages 555-560

  Todeschini, Giuseppe ^a   Tecchio, Cristina ^a   Pasini, Felice ^a   Benedetti, Fabio ^a   Cantini, Maurizio ^a   Crippa, Claudia ^a   Draisci, Michela ^a   Pizzolo, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Chemotherapy; Non Hodgkin lymphoma; Recurrence; Refractory

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ANTHRACYCLINE; ANTIFUNGAL AGENT; BICARBONATE; BLEOMYCIN; CHLORHEXIDINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; FUROSEMIDE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; ITRACONAZOLE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; URATE OXIDASE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BACTERIAL INFECTION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL LINEAGE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; EXFOLIATIVE DERMATITIS; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MUCOSA INFLAMMATION; MYCOSIS; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 22544485966     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21150     Document Type: Article

References (17)

1. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose AraC and dexamethasone (DHAP). Blood. 1988;71:117-122.
2. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169-1176.
3. Cabanillas F, Hagemeister FB, Mc Laughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987;5:407-412.
4. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphomas. J Clin Oncol. 1993;11:1573-1582.
5. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14(Suppl 1):i5-i10.
6. Zinzani PL, Tani M, Molinari AL, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica. 2002;87:816-821.
7. Prince HM, Cramp M, Imrie K, et al. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol. 1996;7:1043-1049.
8. Mantadakis E, Herrera L, Leavey PJ, Bash RO, Winick NJ, Kamen BA. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a Phase II window study. J Clin Oncol. 2000;18:2576-2581.
9. Vitolo U, Liberati AM, Lambertenghi Deliliers G, et al. A multicenter randomized trial by Italian Lymphoma Intergroup (ILI) comparing high dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) versus intensified chemotherapy MegaCEOP in high risk diffuse large cell lymphoma (DLCL): no difference in outcome and toxicity [abstract 3028]. Blood. 2001;98:725a.
10. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091-2097.
11. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicenter Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90:372-376.
12. Gugliemi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the PARMA study. J Clin Oncol. 1998;16:3264-3269.
13. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemotherapy resistant or aggressive lymphoma predicts a poor outcome following reduced-intensity allogeneic progenitor cells transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310-4316.
14. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Bone Marrow Transplant registry. J Clin Oncol. 2001;19:406-413.
15. Jermann M, Jost LM, Taverna CH, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a Phase II study. Ann Oncol. 2004;15:511-516.
16. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE (RICE) as second-line therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684-3688.
17. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920-2924.